Nasdaq:MGX
Metagenomi, Inc.
A Nasdaq-listed life sciences software provider offering cloud-based genomic data management and analytics solutions to accelerate drug discovery and research.
Key Metrics
Investment Thesis
Bull Case
Investors may view MGX as a high-growth opportunity if its proprietary genomic workflows gain significant market traction to reverse current losses, leveraging the expanding next-generation sequencing market and increasing demand for cloud-based data analysis tools in precision medicine.
Bear Case
The stock presents substantial risk due to persistent negative profitability with a $-78.1M net loss, a large retained earnings deficit of $-223.0M, and limited cash on hand relative to operating burn, suggesting the company may struggle to sustain operations without major dilution or acquisition.
About Metagenomi, Inc.
Metagenomi, Inc. (MGX) is a life sciences software company providing cloud-based data management and analytical solutions for genomic research. The firm serves academic institutions, biotechnology companies, and contract research organizations globally with its proprietary workflow platforms. Key products include the Metagenomi platform for processing next-generation sequencing data and managing large-scale biological datasets.
Analysis
Management Discussion
Despite generating $52.3M in revenue, the company reported a net loss of $78.1M driven by substantial operating expenses of $141.2M and significant R&D investments of $109.2M, resulting in a cash burn from operations of $109.1M. While financing activities provided $84.0M in capital, the net change in cash was negative $113.2M due to investing outflows exceeding $88M and proceeds from markable securities, highlighting liquidity pressure.
Industry Overview
The genomics software industry is rapidly evolving as sequencing costs decline and data volumes explode, creating high demand for scalable cloud platforms that can manage petabytes of biological data. Competitors face similar challenges in monetizing complex technical capabilities while navigating a crowded landscape of enterprise-focused bioinformatics solutions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2024 |
|---|---|
| Revenue | $52.3M |
| Cost of Revenue | $0 |
| Gross Profit | $52.3M |
| Operating Expenses | $141.2M |
| Operating Income | $-88.9M |
| R&D | $109.2M |
| G&A | $32.0M |
| Stock-Based Comp | $16.2M |
| Depreciation | $5.4M |
| Other OpEx | $0 |
| Non-Operating Income | $5.3M |
| Interest Income | $14.7M |
| Pre-Tax Income | $-83.6M |
| Income Tax | $-5.5M |
| Continuing Ops | $-78.1M |
| Discontinued Ops | $0 |
| Net Income | $-78.1M |
| Minority Interest | $0 |
| Net to Common | $-78.1M |
| Metric | 2024 |
|---|---|
| Current Assets | $258.0M |
| Cash & Equivalents | $27.4M |
| Prepaid Expenses | $8.4M |
| Other Current Assets | $222.2M |
| Long-Term Assets | $66.6M |
| PP&E (Net) | $17.7M |
| Operating Leases | $39.9M |
| LT Investments | $3.4M |
| Other LT Assets | $5.5M |
| Total Assets | $324.6M |
| Current Liabilities | $37.3M |
| Accounts Payable | $533.0K |
| Current Leases | $5.6M |
| Deferred Revenue | $22.8M |
| Taxes Payable | $0 |
| Other Current Liab | $8.4M |
| Long-Term Liabilities | $52.4M |
| LT Operating Leases | $40.2M |
| Other LT Liab | $2.0M |
| Total Liabilities | $89.7M |
| Shareholders' Equity | $234.9M |
| Paid-In Capital | $457.1M |
| Retained Earnings | $-223.0M |
| AOCI | $709.0K |
| Total L&E | $324.6M |
| Metric | 2024 |
|---|---|
| Net Income (CFO) | $-78.1M |
| Non-Cash Adjustments | $-20.4M |
| Working Capital Changes | $-10.6M |
| Cash from Operations | $-109.1M |
| Capital Expenditures | $3.1M |
| Cash from Investing | $-88.2M |
| Cash from Financing | $84.0M |
| FX Effect | $0 |
| Net Change in Cash | $-113.2M |
| Beginning Cash | $145.9M |
| Ending Cash | $32.6M |
Frequently Asked Questions
How does Metagenomi, Inc. make money?
The company operates primarily through its core platform business delivering genomic analysis software as a service, supplemented by professional services for implementation and support, and licensing of proprietary algorithms to partners in the pharmaceutical and biotech sectors.
What are the main risks for MGX?
Significant operating losses of $78.1M indicate high cash burn rates requiring successful commercialization or strategic financing, heavy reliance on external funding given the deficit in retained earnings of $223.0M, and potential market competition from larger established bioinformatics vendors like Illumina or DNAnexus.
What is MGX's competitive advantage?
MGX possesses deep domain expertise in genomics allowing rapid adaptation to new sequencing technologies, a scalable cloud-native architecture that reduces client infrastructure costs, and a growing ecosystem of pre-built analytical workflows that shorten time-to-insight for researchers.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.